Biozep AS

Is a science-based and innovative Norwegian biopharmaceutical company discovering and developing effective, safe, and affordable drugs for chronic eye diseases. Biozep focuses on eye diseases which lead to vision impairment and vision loss such as age-related macular degeneration (AMD), diabetic retinopathy (DR), and dry eye disease (DED).

​​Our drug substances are based on proprietary lipid-based molecules called Therapeutic Lipids. We have more than 20 years of experience in identifying and validating druggable targets for Therapeutic Lipids.

Biozep has discovered certain Therapeutic Lipids with great potential for treatment of chronic eye diseases. We have identified a lead compound, BIZ-101, based on its potent retina-protective and anti-inflammatory effects documented by convincing in vitro data.  The company will during 2018 and 2019 finalize proof of principle studies in selected animal models.